17 April 2018 - - Canada-based specialty pharmaceutical company Acerus Pharmaceuticals Corp. (TSX: ASP) has signed an agreement granting Mexico City, Mexico-based pharmaceutical company Producto Científicos, S.A. de C.V (Carnot Laboratorios) the exclusive right to market Natesto in 19 Central and Latin American countries, the company said.
The countries are Mexico, Argentina, Columbia, Peru, Chile, Ecuador, Guatemala, El Salvador, Nicaragua, Honduras, Panama, Costa Rica, Cuba, Dominican Republic, Venezuela, Bolivia, Uruguay, Paraguay, and Haiti.
Under the terms of the agreement, Acerus will receive an upfront fee and regulatory milestone payments upon Carnot Laboratorios receiving marketing approval in the territory. In addition, Acerus will receive a supply price for the product.
If approved, Natesto will be the first and only testosterone nasal gel for androgen replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone (hypogonadism) in the 19 countries covered by the agreement.
Natesto (testosterone) nasal gel, available in a 'no-touch' dispenser with a metered dose pump for reduced transference risk, is approved and available in Canada for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone (hypogonadism). It is also approved and available in the US.
Acerus is focused on the development, manufacture, marketing and distribution of innovative, branded products that improve the patient experience, with a primary focus in the field of men's and women's health.
Privately held Carnot Laboratorios is active in Central and Latin American countries directly or via commercial partners. The company employs 1,039 employees including 483 sales representatives. Its main therapeutic areas are gastroenterology, women's health, pediatrics, and respiratory.